Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation

被引:58
作者
Ahlemann, Martin
Zeidler, Reinhard
Lang, Stephan
Mack, Brigitte
Muenz, Markus
Gires, Olivier
机构
[1] Univ Munich, Dept Head & Neck Surg, D-81377 Munich, Germany
[2] Univ Munich, Dept Head & Neck Res, Clin Cooperat Grp Mol Oncol, D-81377 Munich, Germany
[3] GSF Natl Res Ctr Environm & Hlth, Munich, Germany
[4] Univ Hosp Schleswig Holstein, Dept Otorhinolaryngol Head & Neck Surg, Lubeck, Germany
关键词
AMIDA; eIF3i; mTOR; PI3K; rapamycin; mRNA translation;
D O I
10.1002/mc.20269
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Molecular processes controlling mRNA translation are complex, multilayered, and their deregulation can lead to cancer pathogenesis. Eukaryotic initiation factor 3 (eIF3) is involved in the initiation process of protein translation and overexpression of its subunit eukaryotic translation initiation factor i (eIF3i) has been observed in carcinomas. Nevertheless, the potential role of eIF3i in carcinogenesis is poorly understood. Here, we show that in vitro, overexpression of human eIF3i resulted in cell size increase, proliferation enhancement, cell-cycle progression, and anchorage-independent growth. Without external stimuli, eIF3i overexpressing cells arrested in G(1)/G(0) phase, demonstrating the requirement of additional growth signals. inhibition of the kinase mTOR, a key player in the integration of nutrition and growth signals into protein synthesis, with rapamycin reduced serine phosphorylation of eIF3i and resulted in a loss of anchorage-independent growth. Thus, eIF3i overexpression fosters the integration of growth signals by mTOR into the mRNA translation process, promoting protein synthesis and tumor growth. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:957 / 967
页数:11
相关论文
共 31 条
[1]
Conservation and diversity of eukaryotic translation initiation factor eIF3 [J].
Asano, K ;
Kinzy, TG ;
Merrick, WC ;
Hershey, JWB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (02) :1101-1109
[2]
The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[3]
Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO
[4]
2-M
[5]
A WD-DOMAIN PROTEIN THAT IS ASSOCIATED WITH AND PHOSPHORYLATED BY THE TYPE-II TGF-BETA RECEPTOR [J].
CHEN, RH ;
MIETTINEN, PJ ;
MARUOKA, EM ;
CHOY, L ;
DERYNCK, R .
NATURE, 1995, 377 (6549) :548-552
[6]
The type II transforming growth factor (TGF)-β receptor-interacting protein TRIP-1 acts as a modulator of the TGF-β response [J].
Choy, L ;
Derynck, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (47) :31455-31462
[7]
Translational control: the cancer connection [J].
Clemens, MJ ;
Bommer, UA .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1999, 31 (01) :1-23
[8]
Gene-specific regulation by general translation factors [J].
Dever, TE .
CELL, 2002, 108 (04) :545-556
[9]
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E [J].
Fingar, DC ;
Richardson, CJ ;
Tee, AR ;
Cheatham, L ;
Tsou, C ;
Blenis, J .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (01) :200-216
[10]
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression [J].
Fingar, DC ;
Blenis, J .
ONCOGENE, 2004, 23 (18) :3151-3171